GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fabino Life Sciences Ltd (BOM:543444) » Definitions » EBIT

Fabino Life Sciences (BOM:543444) EBIT : ₹0.9 Mil (TTM As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Fabino Life Sciences EBIT?

Fabino Life Sciences's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2024 was ₹-0.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹0.9 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Fabino Life Sciences's annualized ROC % for the quarter that ended in Mar. 2024 was -1.04%. Fabino Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -1.40%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Fabino Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 1.23%.

Fabino Life Sciences EBIT Historical Data

The historical data trend for Fabino Life Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fabino Life Sciences EBIT Chart

Fabino Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBIT
Get a 7-Day Free Trial 3.01 0.49 0.72 0.16 0.87

Fabino Life Sciences Semi-Annual Data
Mar19 Mar20 Mar21 Mar22 Sep22 Mar23 Sep23 Mar24
EBIT Get a 7-Day Free Trial - 0.13 0.03 1.14 -0.27

Competitive Comparison of Fabino Life Sciences's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Fabino Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fabino Life Sciences's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fabino Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Fabino Life Sciences's EV-to-EBIT falls into.


Fabino Life Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fabino Life Sciences  (BOM:543444) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Fabino Life Sciences's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-0.702 * ( 1 - 27.26% )/( (44.207 + 54.443)/ 2 )
=-0.5106348/49.325
=-1.04 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=79.114 - 24.734 - ( 10.173 - max(0, 25.71 - 76.854+10.173))
=44.207

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=153.568 - 98.505 - ( 0.62 - max(0, 98.985 - 149.296+0.62))
=54.443

Note: The Operating Income data used here is two times the semi-annual (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Fabino Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.542/( ( (1.368 + max(32.21, 0)) + (3.427 + max(40.48, 0)) )/ 2 )
=-0.542/( ( 33.578 + 43.907 )/ 2 )
=-0.542/38.7425
=-1.40 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(43.631 + 14.289 + 0) - (24.734 + 0 + 0.976)
=32.21

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(126.119 + 13.346 + -2.8421709430404E-14) - (98.505 + 0 + 0.48)
=40.48

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Fabino Life Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=0.873/70.871
=1.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fabino Life Sciences EBIT Related Terms

Thank you for viewing the detailed overview of Fabino Life Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Fabino Life Sciences (BOM:543444) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fabino Life Sciences Ltd (BOM:543444) » Definitions » EBIT
Comparable Companies
BOM:531541 BOM:524661 BOM:531686 BOM:524516 BOM:530207 BOM:539680 BOM:531762 BOM:540108 BOM:524322 BOM:524590 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
Murthal Road,, Shubham Garden, Jeevan Vihar Extension Near, Sonipat, HR, IND, 131001
Website
https://www.fabinolife.com
Fabino Life Sciences Ltd is a pharmaceutical company. It is engaged in manufacturing, marketing, trading and packing of pharmaceutical and other wellness-focused consumer products. It offers a wide range of allopathic, Food and wellness, Veterinary, Multi-vitamin and herbal products. The company currently supplies in Haryana, Delhi, parts of Punjab, Himachal Pradesh, Eastern Uttar Pradesh, Orissa, and Jharkhand, and parts of West Bengal, Andhra Pradesh, and Nepal.

Fabino Life Sciences (BOM:543444) Headlines

No Headlines